Vertex Pharmaceuticals
VRTX
1,551 hedge funds and large institutions have $110B invested in Vertex Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 174 funds opening new positions, 661 increasing their positions, 517 reducing their positions, and 92 closing their positions.
89% more first-time investments, than exits
New positions opened: 174 | Existing positions closed: 92
28% more repeat investments, than reductions
Existing positions increased: 661 | Existing positions reduced: 517
10% more funds holding in top 10
Funds holding in top 10: 30 → 33 (+3)
4% more funds holding
Funds holding: 1,497 → 1,551 (+54)
5% more capital inflows, than outflows
Capital inflows: $5.67B | Capital outflows: $5.41B
0.01% less ownership
Funds ownership: 91.15% → 91.15% (-0.01%)
22% less call options, than puts
Call options by funds: $681M | Put options by funds: $875M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.21B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$495M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$344M |
| 4 |
Goldman Sachs
New York
|
+$287M |
| 5 |
JP Morgan Chase
New York
|
+$252M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$990M |
| 2 |
BlackRock
New York
|
-$281M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$201M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$189M |
| 5 |
ClearBridge Investments
New York
|
-$147M |
VRTX Hedge Fund Activity: Q2 2024 in Review
1,551 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2024, worth a combined $110B — up 12% from $98B a quarter earlier.
Buyers outnumbered sellers: 174 funds opened new VRTX positions and 92 closed out — a net gain of 82 holders — while 661 added to existing stakes and 517 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $1.21B. The largest seller was T. Rowe Price Associates, cutting an estimated $990M.
- 1,551 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2024, up from 1,497 in Q1 2024.
- Funds reported $110B of Vertex Pharmaceuticals stock for Q2 2024, up 12% quarter-over-quarter.
- 174 funds opened new Vertex Pharmaceuticals positions in Q2 2024 and 92 closed out, a net change of +82 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2024 was Capital Research Global Investors, an estimated $1.21B added.
- The largest Vertex Pharmaceuticals seller in Q2 2024 was T. Rowe Price Associates, an estimated $990M sold.
Based on aggregated 13F filings for Q2 2024.